PHAT Stock Analysis: Buy, Sell, or Hold?
PHAT - Phathom Pharmaceuticals, Inc. Common Stock
$10.61
0.24 (2.31%)
▲
5d:
+6.1%
30d:
-18.7%
90d:
+1.63%
BUY
HIGH Confidence
Analysis Updated: Jun 12, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Smart Money Accumulation
None View Scanner →
Strength: 6.5/10
Get Alerted When PHAT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: PHAT shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: PHAT shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$15.12
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$9.39
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 7.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PHAT is currently trading at $10.61, which is considered fair relative to its 30-day fair value range of $9.89 to $12.02. The stock's valuation (Forward PE: 7.2) is in line with its historical norms (7.5). Remarkably, the market is currently pricing in an annual earnings decline of 1.4% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, PHAT is in a uptrend. The price is approaching resistance at $10.72. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: PHAT has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (26th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $23.70 (+128.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PHAT is in a uptrend. The price is approaching resistance at $10.72. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: PHAT has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (26th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $23.70 (+128.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$9.89 -
$12.02
Company Quality Score
56/100
(HOLD)
Options IV Signal
26th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
86.5%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 26th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 128.5% below Wall St target ($23.70)
Trading Range Analysis
30-Day Trading Range
$9.89 -
$12.02
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$2.14
(20.2%)
Support & Resistance Levels
Support Level
$8.78
Resistance Level
$10.72
Current Trend
Uptrend
Technical data as of
Jun 12, 2026
Fundamental Context
Forward P/E (Next Year Est.)
7.21
Wall Street Target
$23.70
(+128.5%)
Revenue Growth (YoY)
104.4%
Profit Margin
-76.8%
Valuation Discount vs History
-1.4% cheaper
PE vs Historical
7.2 vs 7.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.4%
(market-implied from PE analysis)
1-Year Target
$10.22
(-1%)
2-Year Target
$10.08
(-3%)
3-Year Target
$9.94
(-4%)
3-Yr Target (if PE normalizes)
(PE: 7→8)
$10.35
(0%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 7.2 to 7.5
Stabilization Target:
$10.79
(+4.1%)
PE Expansion Potential:
+4.1%
Share & Embed Analysis
Last updated: June 15, 2026 11:07 AM ET
Data refreshes hourly during market hours. Next update: 12:07 PM
Data refreshes hourly during market hours. Next update: 12:07 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PHAT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 50 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 51 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$275 | 61 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$109 | 59 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$83 | 54 HOLD |
Advanced PHAT Option Strategies
Professional options setups generated by AI based on today's PHAT price and gamma walls.
